Secondary osteoporosis

Endocrine Development

Volumn 16, Issue , 2009, Pages 170-190

  Ahmed, S F ^a   Elmantaser, M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ASPARAGINASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; IFOSFAMIDE; IMMUNOMODULATING AGENT; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; PAMIDRONIC ACID; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; THYROXINE; VALPROIC ACID; VINCRISTINE; VITAMIN D; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA NERVOSA; BONE DENSITOMETRY; BONE DENSITY; BONE DISEASE; BONE FRAGILITY; BONE MINERALIZATION; BONE PAIN; BONE REMODELING; CALCIUM INTAKE; CANCER RADIOTHERAPY; CELL ACTIVITY; CELL DIFFERENTIATION; CEREBRAL PALSY; CHILDHOOD; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; CUSHING SYNDROME; CYSTIC FIBROSIS; DERMATOMYOSITIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; ENTERITIS; EXERCISE; FEVER; FRACTURE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOGONADISM; INBORN ERROR OF METABOLISM; INFLAMMATION; JAW OSTEONECROSIS; JUVENILE RHEUMATOID ARTHRITIS; KLINEFELTER SYNDROME; LEUKEMIA; MALABSORPTION; METABOLIC ACIDOSIS; MYALGIA; NEPHROTIC SYNDROME; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PHYSICAL MOBILITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY OSTEOPOROSIS; SICKLE CELL ANEMIA; SPINAL CORD INJURY; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THALASSEMIA; THYROID DISEASE; TURNER SYNDROME; ULTRASOUND; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; VOMITING; WALKING DIFFICULTY;

ADULT; BONE DENSITY CONSERVATION AGENTS; CHILD; DIPHOSPHONATES; HUMANS; MOBILITY LIMITATION; MOTOR ACTIVITY; OSTEOPOROSIS;

EID: 68149131131     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000223695     Document Type: Review

References (92)

1. Ahmed SF, Horrocks IA, Patterson T, et al: Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J Pediatr Gastroenterol Nutr 2004;38:276-280.
2. Lewiecki EM, Gordon CM, Baim S, et al: International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008;43:1115-1121.
3. Wong SC, Khanna S, Rashid R, Ahmed SF: Auditing bone densitometry and fractures in children with chronic disease. Arch Dis Child 2008;93:705-707.
4. Eastell R, Reid DM, Compston J, et al: Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 2001; 94:575-597.
5. Raisz LG, Rodan GA: Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am 2003;32:15-24.
6. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-227.
7. Krum SA, Brown M: Unraveling estrogen action in osteoporosis. Cell Cycle 2008;7:1348-1352.
8. Weitzmann MN, Pacifici R: The role of T lymphocytes in bone metabolism. Immunol Rev 2005;208: 154-168.
9. Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K: Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol 2004;201:17-25.
10. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y et al.: TSH is a negative regulator of skeletal remodeling. Cell 2003;115:151-162.
11. Koch H, Jadlowiec JA, Campbell PG: Insulin-like growth factor-I induces early osteoblast gene expression in human mesenchymal stem cells. Stem Cells Dev 2005;14:621-631.
12. Giustina A, Mazziotti G, Canalis E: Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29:535-559.
13. Mukherjee A, Rotwein P: Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions. Mol Endocrinol 2008;22: 1238-1250.
14. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C: Androgens and bone. Endocr Rev 2004;25:389-425.
15. Krum SA, Miranda-Carboni GA, Hauschka PV, et al: Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27:535-545.
16. Favus MJ: Primer on the Metabolic Bone Diseases and Disorders of MIneral Metabolism. New York, Academic Press, 2003.
17. Frost HM: Osteoporoses: a rationale for further definitions? Calcif Tissue Int 1998;62:89-94.
18. Tatsumi S, Ishii K, Amizuka N, et al: Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007;5: 464-475.
19. Klein-Nulend J, Bacabac RG, Mullender MG: Mechanobiology of bone tissue. Pathol Biol (Paris) 2005;53:576-580.
20. Tan SD, Kuijpers-Jagtman AM, Semeins CM, et al: Fluid shear stress inhibits TNFalpha-induced osteocyte apoptosis. J Dent Res 2006;85:905-909.
21. Sikavitsas VI, Temenoff JS, Mikos AG: Biomaterials and bone mechanotransduction. Biomaterials 2001; 22:2581-2593.
22. Weinstein RS, Chen JR, Powers CC, et al: Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-1048.
23. O'Brien CA, Jia D, Plotkin LI, et al: Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-1841.
24. Cohran VC, Griffiths M, Heubi JE: Bone mineral density in children exposed to chronic glucocorticoid therapy. Clin Pediatr (Phila) 2008;47:469-475.
25. Cooper MS, Hewison M, Stewart PM: Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol 1999;163:159-164.
26. Mushtaq T, Ahmed SF: The impact of corticosteroids on growth and bone health. Arch Dis Child 2002; 87:93-96.
27. Ward LM: Osteoporosis due to glucocorticoid use in children with chronic illness. Horm Res 2005; 64:209-221.
28. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA: Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002;17:695-702.
29. Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA: Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf) 2002;57:185-191.
30. Crofton PM, Ahmed SF, Wade JC, et al: Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res 2000;48:490-496.
31. Laan R F, Buijs WC, van Erning LJ, et al: Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 1993;52:5-9.
32. Elmantaser M, Stewart G, Gibson B, Ahmed SF: Bone morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Endocrine Abstracts 2008;17:OC10.
33. Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G: Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 2007;48:21-27.
34. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB: Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 2001; 19:3066-3072.
35. van Staa T P, Cooper C, Leufkens HG, Bishop N: Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003;18:913-918.
36. Chitre MM, Hayes W: 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. J Manag Care Pharm 2008;14:281-290.
37. Stein E, Shane E: Secondary osteoporosis. Endocrinol Metab Clin North Am 2003;32:115-34, vii.
38. Munns CF, Cowell CT: Prevention and treatment of osteoporosis in chronically ill children. J Musculo-skelet Neuronal Interact 2005;5:262-272.
39. Shaw NJ: Osteoporosis in paediatrics. Arch Dis Child Educ Pract Ed 2007;92:169-175.
40. Brunner R, Doderlein L: Pathological fractures in patients with cerebral palsy. J Pediatr Orthop B 1996;5:232-238.
41. Sugiyama T, Takaki T, Saito T, Taguchi T: Vitamin K therapy for cortical bone fragility caused by reduced mechanical loading in a child with hemiplegia. J Musculoskelet Neuronal Interact 2007;7:219-223.
42. Houde S, Filiatrault M, Fournier A, et al: Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-206.
43. Soderpalm AC, Magnusson P, Ahlander AC, et al: Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 2007;17:919-928.
44. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A: Osteopenia in men with a history of delayed puberty. N Engl J Med 1992;326:600-604.
45. Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Saggese G: Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998;83:4280-4283.
46. Aris RM, Merkel PA, Bachrach LK, et al: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90:1888-1896.
47. Bouillon R, Koledova E, Bezlepkina O, et al: Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 2004;89:4993-4998.
48. Holmer H, Svensson J, Rylander L, et al: Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res 2007;22:1842-1850.
49. Leger J, Ruiz JC, Guibourdenche J, Kindermans C, Garabedian M, Czernichow P: Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged l-thyroxine therapy. Acta Paediatr 1997;86:704-710.
50. Pitukcheewanont P, Safani D, Gilsanz V, Klein M, Chongpison Y, Costin G: Quantitative computed tomography measurements of bone mineral density in prepubertal children with congenital hypothyroidism treated with l-thyroxine. J Pediatr Endocrinol Metab 2004;17:889-893.
51. Numbenjapon N, Costin G, Gilsanz V, Pitukcheewanont P: Low cortical bone density measured by computed tomography in children and adolescents with untreated hyperthyroidism. J Pediatr 2007; 150:527-530.
52. Brandao FR, Vicente EJ, Daltro CH, Sacramento M, Moreira A, Adan L: Bone metabolism is linked to disease duration and metabolic control in type 1 diabetes mellitus. Diabetes Res Clin Pract 2007;78: 334-339.
53. Chau DL, Edelman S V, Chandran M: Osteoporosis and diabetes. Curr Diab Rep 2003;3:37-42.
54. Greer FR, Krebs NF: Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006;117:578-585.
55. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80:1678S-1688S.
56. Ward LM, Glorieux FH: The spectrum of pediatric osteoporosis; in Glorieux FH, Pettifor JM, Juppner H (eds): Pediatric Bone: Biology and Diseases. New York, Academic Press, 2003, pp 401-442.
57. Pack A: Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008; 17:181-186.
58. Drezner MK: Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5(suppl 2):S41-S47.
59. Hurley MM, Gronowicz G, Kream BE, Raisz LG: Effect of heparin on bone formation in cultured fetal rat calvaria. Calcif Tissue Int 1990;46:183-188.
60. Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG: Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 2002;100:2530-2536.
61. Ariyoshi W, Takahashi T, Kanno T, et al: Heparin inhibits osteoclastic differentiation and function. J Cell Biochem 2008;103:1707-1717.
62. Ragab AH, Frech RS, Vietti TJ: Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970;25:580-585.
63. Crofton PM, Ahmed SF, Wade JC, et al: Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998;83:3121-3129.
64. Scheven BA, van der Veen MJ, Damen CA, Lafeber F P, Van Rijn HJ, Bijlsma JW et al.: Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3. J Bone Miner Res 1995;10:874-880.
65. Davies JH, Evans BA, Jenney ME, Gregory JW: Effects of chemotherapeutic agents on the function of primary human osteoblast-like cells derived from children. J Clin Endocrinol Metab 2003;88:6088- 6097.
66. Bianchi ML: How to manage osteoporosis in children. Best Pract Res Clin Rheumatol 2005;19:991- 1005.
67. Binkley TL, Berry R, Specker BL: Methods for measurement of pediatric bone. Rev Endocr Metab Disord 2008;9:95-106.
68. Clark EM, Tobias JH, Ness AR: Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics 2006;117: e291-e297.
69. Kaji H, Yamauchi M, Chihara K, Sugimoto T: The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 2006;53:27-34.
70. Crabtree NJ, Kibirige MS, Fordham JN, et al: The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004;35:965-972.
71. McDevitt H, Ahmed SF: Quantitative ultrasound assessment of bone health in the neonate. Neonatology 2007;91:2-11.
72. Pluskiewicz W, Drozdzowska B, Lyssek-Boron A, Bielecki T, Adamczyk P, Sawaryn P et al.: Densitometric and quantitative ultrasound measurements and laboratory investigations in wheelchair-bound patients. J Clin Densitom 2006;9: 78-83.
73. Hangartner TN, Gilsanz V: Evaluation of cortical bone by computed tomography. J Bone Miner Res 1996;11:1518-1525.
74. Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol 2007;264:164-170.
75. Iwasaki T, Takei K, Nakamura S, Hosoda N, Yokota Y, Ishii M: Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatr Int 2008;50:269-275.
76. Jekovec-Vrhovsek M, Kocijancic A, Prezelj J: Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000;42:403-405.
77. Verschueren SM, Roelants M, Delecluse C, Swinnen S, Vanderschueren D, Boonen S: Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmeno-pausal women: a randomized controlled pilot study. J Bone Miner Res 2004;19:352-359.
78. Chad KE, Bailey DA, McKay HA, Zello GA, Snyder RE: The effect of a weight-bearing physical activity program on bone mineral content and estimated volumetric density in children with spastic cerebral palsy. J Pediatr 1999;135:115-117.
79. Gilsanz V, Wren TA, Sanchez M, Dorey F, Judex S, Rubin C: Low-level, high-frequency mechanical signals enhance musculoskeletal development of young women with low BMD. J Bone Miner Res 2006;21: 1464-1474.
80. Ward K, Alsop C, Caulton J, Rubin C, Adams J, Mughal Z: Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res 2004;19:360-369.
81. Glorieux FH, Rauch F, Shapiro JR: Bisphosphonates in children with bone diseases. N Engl J Med 2003; 349:2068-2071.
82. Ward LM, Tricco A, Phuong P-N, et al: Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database System Rev 2007;4:1-38.
83. Bachrach LK, Ward LM: Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-409..
84. Whyte M P, Wenkert D, Clements KL, McAlister WH, Mumm S: Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-463.
85. Issenman RM, Atkinson SA, Radoja C, Fraher L: Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:401-406.
86. Semeao EJ, Stallings VA, Peck SN, Piccoli DA: Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997;112: 1710-1713.
87. Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory J W, Jenkins HR: Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 1997;76:325-329.
88. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM: Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998;42:188-194.
89. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998;114:902-911.
90. Herzog D, Bishop N, Glorieux F, Seidman EG: Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis 1998;4:261-267.
91. Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA: Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis 1999;5:161-166.
92. Mauras N, George D, Evans J, et al: Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002;51:127-135.